» Articles » PMID: 26636648

ACSL4 Promotes Prostate Cancer Growth, Invasion and Hormonal Resistance

Overview
Journal Oncotarget
Specialty Oncology
Date 2015 Dec 5
PMID 26636648
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Increases in fatty acid metabolism have been demonstrated to promote the growth and survival of a variety of cancers, including prostate cancer (PCa). Here, we examine the expression and function of the fatty acid activating enzyme, long-chain fatty acyl-CoA synthetase 4 (ACSL4), in PCa. Ectopic expression of ACSL4 in ACSL4-negative PCa cells increases proliferation, migration and invasion, while ablation of ACSL4 in PCa cells expressing endogenous ACSL4 reduces cell proliferation, migration and invasion. The cell proliferative effects were observed both in vitro, as well as in vivo. Immunohistochemical analysis of human PCa tissue samples indicated ACSL4 expression is increased in malignant cells compared with adjacent benign epithelial cells, and particularly increased in castration-resistant PCa (CRPC) when compared with hormone naive PCa. In cell lines co-expressing both ACSL4 and AR, proliferation was independent of exogenous androgens, suggesting that ACSL4 expression may lead to CRPC. In support for this hypothesis, ectopic ACSL4 expression induced resistance to treatment with Casodex, via decrease in apoptosis. Our studies further indicate that ACSL4 upregulates distinct pathway proteins including p-AKT, LSD1 and β-catenin. These results suggest ACSL4 could serve as a biomarker and potential therapeutic target for CRPC.

Citing Articles

Ferroptosis and its impact on common diseases.

Zou P, He Q, Xia H, Zhong W PeerJ. 2024; 12:e18708.

PMID: 39713140 PMC: 11663406. DOI: 10.7717/peerj.18708.


Mechanisms and cross-talk of regulated cell death and their epigenetic modifications in tumor progression.

He R, Liu Y, Fu W, He X, Liu S, Xiao D Mol Cancer. 2024; 23(1):267.

PMID: 39614268 PMC: 11606237. DOI: 10.1186/s12943-024-02172-y.


Polygenic anti-cancer activity of in prostate cancer induced animal model.

Alabi G, Elekofehinti O, Sanni D, Ashaolu J, Oluwatuyi A Toxicol Rep. 2024; 13:101774.

PMID: 39554609 PMC: 11567122. DOI: 10.1016/j.toxrep.2024.101774.


Prognostic Values of Ferroptosis-Related Proteins ACSL4, SLC7A11, and CHAC1 in Cholangiocarcinoma.

Amontailak S, Titapun A, Jusakul A, Thanan R, Kimawaha P, Jamnongkan W Biomedicines. 2024; 12(9).

PMID: 39335604 PMC: 11428419. DOI: 10.3390/biomedicines12092091.


Ferroptosis-related gene signature and clinical prognostic factors as prognostic marker for colon adenocarcinoma.

Zeng Q, Han L, Hong Q, Wang G, Xue X, Fang Y Heliyon. 2024; 10(14):e33794.

PMID: 39100449 PMC: 11295570. DOI: 10.1016/j.heliyon.2024.e33794.


References
1.
Karantanos T, Corn P, Thompson T . Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 2013; 32(49):5501-11. PMC: 3908870. DOI: 10.1038/onc.2013.206. View

2.
Liang Y, Wu C, Chu J, Wang C, Hung L, Wang Y . Involvement of fatty acid-CoA ligase 4 in hepatocellular carcinoma growth: roles of cyclic AMP and p38 mitogen-activated protein kinase. World J Gastroenterol. 2005; 11(17):2557-63. PMC: 4305743. DOI: 10.3748/wjg.v11.i17.2557. View

3.
Qiao S, Tuohimaa P . The role of long-chain fatty-acid-CoA ligase 3 in vitamin D3 and androgen control of prostate cancer LNCaP cell growth. Biochem Biophys Res Commun. 2004; 319(2):358-68. DOI: 10.1016/j.bbrc.2004.05.014. View

4.
Hughes-Fulford M, Li C, Boonyaratanakornkit J, Sayyah S . Arachidonic acid activates phosphatidylinositol 3-kinase signaling and induces gene expression in prostate cancer. Cancer Res. 2006; 66(3):1427-33. DOI: 10.1158/0008-5472.CAN-05-0914. View

5.
Mashima T, Sato S, Okabe S, Miyata S, Matsuura M, Sugimoto Y . Acyl-CoA synthetase as a cancer survival factor: its inhibition enhances the efficacy of etoposide. Cancer Sci. 2009; 100(8):1556-62. PMC: 11158289. DOI: 10.1111/j.1349-7006.2009.01203.x. View